Patients and Caregivers – Baqsimi

Worried about severe low blood sugar?

BAQSIMI is here to help

BAQSIMI^® is a medicine used to treat severe low blood sugar. It’s given to someone during a low blood sugar emergency (severe hypoglycemia) when they are unable to eat, drink, or swallow sugar on their own, and it’s meant for adults and children 4 years and above who take insulin for diabetes.

Answer these simple questions to find out if BAQSIMI is right for you:

1. Do you have diabetes and take insulin?

2. Have you ever had any of these low blood sugar symptoms?

Mood swings

Dizziness or blurred vision

Lack of coordination

Difficulty thinking and speaking

Seizure or loss of consciousness

3. Have you ever needed another person’s help during a low blood sugar emergency?

4. Have you ever experienced a time when you were unwilling or unable to consume oral carbs?

5. Have you ever had a blood sugar level below 2.8 mmol/L?

6. Do you ever worry or feel anxious about experiencing a low blood sugar emergency?

If you answered ‘yes’ to any of the questions above, ask your doctor about a rescue plan that includes BAQSIMI.

You may be at risk of low blood sugar emergencies and might have already experienced one in the past if you answered ‘yes’ to any of the questions above. To help you bring this up with your doctor, download and share the following guide.

Download the guide

BAQSIMI Sealed tube and nasal delivery spray system

Continue to What is BAQSIMI?

Indications and Important Safety Information

Clinical use:
BAQSIMI has not been studied in pediatric patients less than 4 years old.

Limited clinical trial experience has not identified difference in responses between elderly (≥65 years of age) and younger patients.

Contraindications:

Hypersensitivity to glucagon or to any ingredient in the formulation or container
Pheochromocytoma
Insulinoma

Most serious warnings and precautions:
Lack of response: BAQSIMI should be given only in patients where impaired consciousness precludes oral carbohydrates. After intranasal administration of BAQSIMI, the patient will normally respond within 15 minutes. If the patient does not respond within 15 minutes, intravenous glucose must be administered as soon as IV access can be established.

States of starvation, adrenal insufficiency or chronic hypoglycemia: Because glucagon is of little or no help in these cases, intravenous glucose should be used for the treatment of hypoglycemia in these conditions.

Other relevant warnings and precautions:

Cardiovascular effects
Driving and operating machinery
Pheochromocytoma
Insulinoma
Sensitivity and resistance to glucagon
Pregnant women
Breast-feeding
Pediatrics (<4 years of age)
Geriatrics (≥65 years of age)
Use in patients with Type 2 diabetes taking sulfonylureas
Use with alcohol
Monitoring and laboratory tests

For more information:
Consult the Product Monograph at https://pdf.hres.ca/dpd_pm/00074561.PDF for additional important information relating to warnings and precautions, adverse reactions, drug interactions and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-423-4136.

Indications and Important Safety Information

Clinical use:
BAQSIMI has not been studied in pediatric patients less than 4 years old.

Limited clinical trial experience has not identified difference in responses between elderly (≥65 years of age) and younger patients.

Contraindications:

Hypersensitivity to glucagon or to any ingredient in the formulation or container
Pheochromocytoma
Insulinoma

Most serious warnings and precautions:
Lack of response: BAQSIMI should be given only in patients where impaired consciousness precludes oral carbohydrates. After intranasal administration of BAQSIMI, the patient will normally respond within 15 minutes. If the patient does not respond within 15 minutes, intravenous glucose must be administered as soon as IV access can be established.

States of starvation, adrenal insufficiency or chronic hypoglycemia: Because glucagon is of little or no help in these cases, intravenous glucose should be used for the treatment of hypoglycemia in these conditions.

Other relevant warnings and precautions:

Cardiovascular effects
Driving and operating machinery
Pheochromocytoma
Insulinoma
Sensitivity and resistance to glucagon
Pregnant women
Breast-feeding
Pediatrics (<4 years of age)
Geriatrics (≥65 years of age)
Use in patients with Type 2 diabetes taking sulfonylureas
Use with alcohol
Monitoring and laboratory tests

For more information:
Consult the Product Monograph at https://pdf.hres.ca/dpd_pm/00074561.PDF for additional important information relating to warnings and precautions, adverse reactions, drug interactions and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-423-4136.